Filetype Excel XLSX | Posted on 14 Aug 2022 | 3 years ago
Authentication
digital resources
172x Filetype XLSX File size 0.07 MB Source: www.sanofi.com
Sheet 1: 2016 Business Net Income Q1
| Segment results first-quarter | ||||||||||||||
| First-quarter 2016 | Pharmaceuticals | Vaccines | Others | Total Group | ||||||||||
| € million | Q1 2016 | Q1 2015 | Change | Q1 2016 | Q1 2015 | Change | Q1 2016 | Q1 2015 | Q1 2016 | Q1 2015 | Change | |||
| Net sales | 7,158 | 7,455 | (4.0%) | 625 | 597 | 4.7% | 7,783 | 8,052 | (3.3%) | |||||
| Other revenues (1) | 54 | 62 | (12.9%) | 91 | 106 | (14.2%) | 145 | 168 | (13.7%) | |||||
| Cost of Sales | (2,097) | (2,190) | (4.2%) | (350) | (376) | (6.9%) | (2,447) | (2,566) | (4.6%) | |||||
| As % of net sales | (29.3%) | (29.4%) | (56.0%) | (63.0%) | (31.4%) | (31.9%) | ||||||||
| Gross Profit | 5,115 | 5,327 | (4.0%) | 366 | 327 | 11.9% | 5,481 | 5,654 | (3.1%) | |||||
| As % of net sales | 71.5% | 71.5% | 58.6% | 54.8% | 70.4% | 70.2% | ||||||||
| Research and development expenses | (1,108) | (1,039) | 6.6% | (127) | (120) | 5.8% | (1,235) | (1,159) | 6.6% | |||||
| As % of net sales | (15.5%) | (13.9%) | (20.3%) | (20.1%) | (15.9%) | (14.4%) | ||||||||
| Selling and general expenses | (2,046) | (2,094) | (2.3%) | (166) | (156) | 6.4% | (2,212) | (2,250) | (1.7%) | |||||
| As % of net sales | (28.6%) | (28.1%) | (26.6%) | (26.1%) | (28.4%) | (27.9%) | ||||||||
| Other operating income/expenses | 107 | (28) | 1 | (14) | (40) | 93 | (67) | |||||||
| Share of profit/loss of associates* and joint ventures | 16 | 32 | 7 | (1) | 23 | 31 | ||||||||
| Net income attributable to non controlling interests | (27) | (33) | (27) | (33) | ||||||||||
| Business operating income | 2,057 | 2,165 | (5.0%) | 80 | 51 | 56.9% | (14) | (40) | 2,123 | 2,176 | (2.4%) | |||
| As % of net sales | 28.7% | 29.0% | 12.8% | 8.5% | 27.3% | 27.0% | ||||||||
| Financial income & expenses | (117) | (96) | ||||||||||||
| Income tax expenses | (455) | (491) | ||||||||||||
| Tax rate** | 22.6% | 23.6% | ||||||||||||
| Business net income excl. Animal Health business | 1,551 | 1,589 | (2.4%) | |||||||||||
| As % of net sales | 19.9% | 19.7% | ||||||||||||
| Business net income of Animal Health business | 171 | 137 | 24.8% | |||||||||||
| Business net income | 1,722 | 1,726 | (0.2%) | |||||||||||
| Business earnings / share excluding Animal Health business (in €)*** |
1.20 | 1.21 | (0.8%) | |||||||||||
| Business earnings / share (in €)*** | 1.34 | 1.32 | 1.5% | |||||||||||
| * Net of tax. | ||||||||||||||
| ** Determined on the basis of Business income before tax, associates and non-controlling interests (excluding Animal Health business). | ||||||||||||||
| *** Based on an average number of shares outstanding of 1,288.4 million in the first quarter of 2016 and 1,308.4 million in the first quarter of 2015. | ||||||||||||||
| (1) As per a change in accounting presentation, Vaxserve sales of non-Group products are reported in Other revenues from 2016 onwards. Prior period Net sales and Other revenues have been represented accordingly. | ||||||||||||||
| Segment results second-quarter 2016 | ||||||||||||||
| Second-quarter 2016 | Pharmaceuticals | Vaccines | Others | Total Group | ||||||||||
| € million | Q2 2016 | Q2 2015 | Change | Q2 2016 | Q2 2015 | Change | Q2 2016 | Q2 2015 | Q2 2016 | Q2 2015 | Change | |||
| Net sales | 7,346 | 7,800 | (5.8%) | 797 | 777 | 2.6% | 8,143 | 8,577 | (5.1%) | |||||
| Other revenues (1) | 68 | 67 | 1.5% | 97 | 118 | (17.8%) | 165 | 185 | (10.8%) | |||||
| Cost of Sales | (2,046) | (2,252) | (9.1%) | (477) | (450) | 6.0% | (2,523) | (2,702) | (6.6%) | |||||
| As % of net sales | (27.9%) | (28.9%) | (59.8%) | (57.9%) | (31.0%) | (31.5%) | ||||||||
| Gross Profit | 5,368 | 5,615 | (4.4%) | 417 | 445 | (6.3%) | 5,785 | 6,060 | (4.5%) | |||||
| As % of net sales | 73.1% | 72.0% | 52.3% | 57.3% | 71.0% | 70.7% | ||||||||
| Research and development expenses | (1,138) | (1,104) | 3.1% | (141) | (142) | (0.7%) | (1,279) | (1,246) | 2.6% | |||||
| As % of net sales | (15.5%) | (14.2%) | (17.7%) | (18.3%) | (15.7%) | (14.5%) | ||||||||
| Selling and general expenses | (2,215) | (2,216) | (0.0%) | (182) | (188) | (3.2%) | (2,397) | (2,404) | (0.3%) | |||||
| As % of net sales | (30.2%) | (28.4%) | (22.8%) | (24.2%) | (29.4%) | (28.0%) | ||||||||
| Other operating income/expenses | 3 | (11) | (1) | 1 | (25) | (15) | (23) | (25) | ||||||
| Share of profit/loss of associates* and joint ventures | 28 | 29 | 2 | 1 | 30 | 30 | ||||||||
| Net income attributable to non controlling interests | (23) | (29) | (23) | (29) | ||||||||||
| Business operating income | 2,023 | 2,284 | (11.4%) | 95 | 117 | (18.8%) | (25) | (15) | 2,093 | 2,386 | (12.3%) | |||
| As % of net sales | 27.5% | 29.3% | 11.9% | 15.1% | 25.7% | 27.8% | ||||||||
| Financial income & expenses | (74) | (109) | ||||||||||||
| Income tax expenses | (467) | (560) | ||||||||||||
| Tax rate** | 23.2% | 24.6% | ||||||||||||
| Business net income excl. Animal Health business | 1,552 | 1,717 | (9.6%) | |||||||||||
| As % of net sales | 19.1% | 20.0% | ||||||||||||
| Business net income of Animal Health business | 128 | 123 | 4.1% | |||||||||||
| Business net income | 1,680 | 1,840 | (8.7%) | |||||||||||
| Business earnings / share excluding Animal Health business (in €)*** |
1.21 | 1.31 | (7.6%) | |||||||||||
| Business earnings / share (in €)*** | 1.31 | 1.41 | (7.1%) | |||||||||||
| * Net of tax. | ||||||||||||||
| ** Determined on the basis of Business income before tax, associates and non-controlling interests (excluding Animal Health business). | ||||||||||||||
| *** Based on an average number of shares outstanding of 1,286.8 million in the second quarter of 2016 and 1,305.9 million in the second quarter of 2015. | ||||||||||||||
| (1) As per a change in accounting presentation, Vaxserve sales of non-Group products are reported in Other revenues from 2016 onwards. Prior period Net sales and Other revenues have been represented accordingly. | ||||||||||||||
| Segment results first-half 2016 | ||||||||||||||
| First-Half 2016 | Pharmaceuticals | Vaccines | Others | Total Group | ||||||||||
| € million | H1 2016 | H1 2015 | Change | H1 2016 | H1 2015 | Change | H1 2016 | H1 2015 | H1 2016 | H1 2015 | Change | |||
| Net sales | 14,504 | 15,255 | (4.9%) | 1,422 | 1,374 | 3.5% | 15,926 | 16,629 | (4.2%) | |||||
| Other revenues (1) | 122 | 129 | (5.4%) | 188 | 224 | (16.1%) | 310 | 353 | (12.2%) | |||||
| Cost of Sales | (4,143) | (4,442) | (6.7%) | (827) | (826) | 0.1% | (4,970) | (5,268) | (5.7%) | |||||
| As % of net sales | (28.6%) | (29.1%) | (58.2%) | (60.1%) | (31.2%) | (31.7%) | ||||||||
| Gross Profit | 10,483 | 10,942 | (4.2%) | 783 | 772 | 1.4% | 11,266 | 11,714 | (3.8%) | |||||
| As % of net sales | 72.3% | 71.7% | 55.1% | 56.2% | 70.7% | 70.4% | ||||||||
| Research and development expenses | (2,246) | (2,143) | 4.8% | (268) | (262) | 2.3% | (2,514) | (2,405) | 4.5% | |||||
| As % of net sales | (15.5%) | (14.0%) | (18.8%) | (19.1%) | (15.8%) | (14.5%) | ||||||||
| Selling and general expenses | (4,261) | (4,310) | (1.1%) | (348) | (344) | 1.2% | (4,609) | (4,654) | (1.0%) | |||||
| As % of net sales | (29.4%) | (28.3%) | (24.5%) | (25.0%) | (28.9%) | (28.0%) | ||||||||
| Other operating income/expenses | 110 | (39) | (1) | 2 | (39) | (55) | 70 | (92) | ||||||
| Share of profit/loss of associates* and joint ventures | 44 | 61 | 9 | 53 | 61 | |||||||||
| Net income attributable to non controlling interests | (50) | (62) | (50) | (62) | ||||||||||
| Business operating income | 4,080 | 4,449 | (8.3%) | 175 | 168 | 4.2% | (39) | (55) | 4,216 | 4,562 | (7.6%) | |||
| As % of net sales | 28.1% | 29.2% | 12.3% | 12.2% | 26.5% | 27.4% | ||||||||
| Financial income & expenses | (191) | (205) | ||||||||||||
| Income tax expenses | (922) | (1,051) | ||||||||||||
| Tax rate** | 22.9% | 24.1% | ||||||||||||
| Business net income excl. Animal Health business | 3,103 | 3,306 | (6.1%) | |||||||||||
| As % of net sales | 19.5% | 19.9% | ||||||||||||
| Business net income of Animal Health business | 299 | 260 | 15.0% | |||||||||||
| Business net income | 3,402 | 3,566 | (4.6%) | |||||||||||
| Business earnings / share excluding Animal Health business (in €)*** |
2.41 | 2.53 | (4.7%) | |||||||||||
| Business earnings / share (in €)*** | 2.64 | 2.73 | (3.3%) | |||||||||||
| * Net of tax. | ||||||||||||||
| ** Determined on the basis of Business income before tax, associates and non-controlling interests (excluding Animal Health business). | ||||||||||||||
| *** Based on an average number of shares outstanding of 1,287.6 million in the first-half 2016 and 1,307.2 million in the first-half 2015. | ||||||||||||||
| (1) As per a change in accounting presentation, Vaxserve sales of non-Group products are reported in Other revenues from 2016 onwards. Prior period Net sales and Other revenues have been represented accordingly. | ||||||||||||||
no reviews yet
Please Login to review.
